DVA vs ENSG
DaVita and The Ensign Group, Inc., both Healthcare
DaVita is the larger company at $12B against $10B. On trailing earnings DVA is the cheaper of the two at a P/E of 14.9 against 27.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year DVA returned +38% against -0.3% for ENSG. The RyuScore puts DVA ahead, 72 against 67 out of 100.
| Figure | DVA | ENSG |
|---|---|---|
| Last close | $181 | $176 |
| Market cap | $12B | $10B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.9 | 27.6 |
| Dividend yield | n/a | 0.1% |
| 1-year return | +38% | -0.3% |
| 5-year return | +55% | +137% |
| RyuScoresector-relative, 1–10 | 72/100 | 67/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
DaVita
Revenue of $3.6B in Q2 2026, net income $265M. Its largest reported line is U.S.Dialysis With Intersegment, 56% of the disclosed total.
The Ensign Group, Inc.
Revenue of $1.4B in Q2 2026, net income $100M. Its largest reported line is Skilled Services, 96% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.